Recent Articles from GlobeNewswire

Assembly Biosciences Announces Pricing of $100 Million Offering of Common Stock and Pre-Funded Warrants
SOUTH SAN FRANCISCO, Calif., May 22, 2026 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral and liver diseases, today announced the pricing of an underwritten, registered offering (the offering) of an aggregate of 3,358,602 shares of common stock at an offering price per share of common stock of $26.50, and, to certain investors in lieu of common stock, pre-funded warrants to purchase up to 415,000 shares of common stock at an offering price per pre-funded warrant of $26.499, which represents the per share offering price of the common stock less the $0.001 exercise price per share for each pre-funded warrant. Gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses, are expected to be approximately $100 million. Assembly Bio has also granted the underwriters a 30-day option to purchase up to an additional 566,040 shares of common stock at the offering price, less underwriting discounts and commissions.
By Assembly Biosciences, Inc. · Via GlobeNewswire · May 22, 2026
Bitget Turns “Crypto Is Dead” Into a Comeback with Bitcoin Pizza Day Campaign ‘Flip the Slice’
By Bitget Limited · Via GlobeNewswire · May 22, 2026
Greece Golden Visa Sees Growing Demand from Single Child Families, Get Golden Visa Reports
LONDON, May 22, 2026 (GLOBE NEWSWIRE) -- According to Get Golden Visa’s internal data, one in five real estate investments under Greece Golden Visa program is made by families planning for their children’s future education. Once, investors mainly preferred this flexible route for its Schengen mobility and capital appreciation potential; now the landscape indicates that Greece Golden Visa program has become a tool for broader lifestyle and education planning.
By Get Golden Visa · Via GlobeNewswire · May 22, 2026
Concorde International Group Proprietary Security Model Featured on World FM Day 2026
SINGAPORE, May 22, 2026 (GLOBE NEWSWIRE) -- Concorde International Group Ltd. (NASDAQ: YOOV) (the “Company”), an integrated provider of technology-enabled security solutions, today highlighted its continued recognition in the facilities security industry, reflecting more than a decade of leadership in delivering comprehensive security services through its proprietary operational model.
Otarmeni™ (lunsotogene parvec) Receives EMA Filing Acceptance for Genetic Hearing Loss
TARRYTOWN, N.Y., May 22, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the European Medicines Agency (EMA) has accepted for review under Accelerated Assessment the Marketing Authorization Application (MAA) for Otarmeni™ (lunsotogene parvec), an in vivo adeno-associated virus vector-based gene therapy for the treatment of biallelic OTOF variant-associated hearing loss. Otarmeni, formerly known as DB-OTO, previously received Orphan Designation from the EMA. If approved, Otarmeni will be the first gene therapy for OTOF-related hearing loss in the European Union (EU).
Chagee to Announce First Quarter 2026 Financial Results on May 28, 2026
SHANGHAI, May 22, 2026 (GLOBE NEWSWIRE) -- Chagee Holdings Limited (NASDAQ: CHA) (“Chagee” or the “Company”), a leading premium tea drinks brand serving healthy and delicious freshly-made tea drinks, today announced that it plans to report its financial results for the first quarter ended March 31, 2026, after the U.S. market closes on May 28, 2026.
By Chagee Holdings Limited · Via GlobeNewswire · May 22, 2026
Destination XL Group, Inc. to Review Unsolicited Tender Offer From Zodiac Partners II
No Shareholder Action Required at this Time
By Destination XL Group, Inc. · Via GlobeNewswire · May 22, 2026
AC Immune Presents New Phase 1 Data Indicating Higher Uptake of TDP-43 PET Tracer ACI-19626 in Patients with ALS
AC Immune Presents New Phase 1 Data Indicating Higher Uptake of TDP-43 PET Tracer ACI-19626 in Patients with ALS
By AC Immune SA · Via GlobeNewswire · May 22, 2026
Silver Singapore Futures Now Live for Trading on Abaxx Exchange
New physically deliverable 1,000 oz, four-nines silver contract supports price discovery and risk management for global industrial silver markets
By Abaxx Technologies Inc. · Via GlobeNewswire · May 22, 2026
Assembly Biosciences Announces Expansion of ABI-6250 Clinical Development Into Cholestatic Liver Diseases
– Phase 2 study in cholestatic liver diseases, focused on PBC and PSC, anticipated to initiate in Q1 2027 –– Builds on completed Phase 1a study and ongoing development in HDV –
By Assembly Biosciences, Inc. · Via GlobeNewswire · May 22, 2026
Mission Success: Rocket Lab Completes 9th Electron Launch for Synspective
MAHIA, New Zealand, May 22, 2026 (GLOBE NEWSWIRE) -- Rocket Lab Corporation (Nasdaq: RKLB), a global leader in launch services and space systems, today announced the successful deployment of the latest satellite for Synspective, marking the ninth dedicated mission Rocket Lab has completed for the Japan-based Earth observation constellation. This launch further strengthens one of the most consistent commercial launch partnerships in the small satellite sector and highlights Electron's industry-leading dedicated launch service.
By Rocket Lab Corporation · Via GlobeNewswire · May 22, 2026
LyondellBasell announces quarterly dividend
HOUSTON and LONDON, May 22, 2026 (GLOBE NEWSWIRE) -- LyondellBasell (NYSE: LYB) today announced it has declared a dividend of $0.69 per share, to be paid to shareholders on June 8, 2026, with an ex-dividend and record date of June 1, 2026.
By LyondellBasell · Via GlobeNewswire · May 22, 2026
FTAI Aviation Prices Inaugural Asset-Backed Securitization
$612 Million Issuance Backed by Aircraft Receives Strong Investor Reception and Marks Strategic Entry into ABS Capital Markets
By FTAI Aviation Ltd. · Via GlobeNewswire · May 22, 2026
Yimutian’s WolaiCai AI Agent Goes Live Across All Platforms: 200 Million Daily Token Consumption, Agricultural AI Revenue Exceeds US$3,000 Per Day
BEIJING, May 22, 2026 (GLOBE NEWSWIRE) -- Yimutian Inc. (Nasdaq: YMT) (“Yimutian” or the “Company”), a leading AI-driven agricultural digital service company in China, today announced that its WolaiCai AI Agent has been fully deployed across all platforms. The system now consumes over 200 million tokens daily, with agricultural AI-related products generating more than RMB20,000 (approximately US$3,000) in daily revenue. As AI enhances user service efficiency, the Company’s agricultural AI strategy continues to deliver growing commercial returns, demonstrating both industrial and commercial value.
By Yimutian Inc. · Via GlobeNewswire · May 22, 2026
MEXC SPACEX(PRE) Launchpad Subscriptions Surpass $56 million, with the Offering Oversubscribed by Up to 15.5x
By MEXC · Via GlobeNewswire · May 22, 2026
Titan Provides Update on Management Changes
GOUVERNEUR, N.Y., May 22, 2026 (GLOBE NEWSWIRE) -- Titan Mining Corporation (“Titan” or the “Company”), an existing zinc concentrate producer in upstate New York and the only U.S. end-to-end producer of natural flake graphite, is pleased to announce the appointment of Mr. Matthew Melnyk, CPG, M.Sc., as Vice President, Geology and Exploration, and Ms. Ashley Kates, CPA, CA, as Interim Chief Financial Officer of the Company, effective May 22, 2026, following Mr. Kevin Hart’s decision to resign for personal reasons.
By Titan Mining Corporation · Via GlobeNewswire · May 22, 2026
Lixiang Education Regains Compliance with Nasdaq Minimum Bid Price Requirement
LISHUI, China, May 22, 2026 (GLOBE NEWSWIRE) -- Lixiang Education Holding Co., Ltd. (the “Company” or NASDAQ: LXEH), a prestigious private education service provider in China, today announced that on May 21, 2026, it received a letter from the Listing Qualification Department of Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that for the last 10 consecutive business days, from May 7, 2026 to May 20, 2026, the closing bid price of the Company’s American Depositary Shares has been at $1.00 per share or greater. Accordingly, the Company has regained compliance with Listing Rule 5450(a)(1), and this matter is now closed.
Market Analysis: Dmitry Shubov Reviews The U.S. Legal-Tech Consolidation Wave and What It Means for S.E.A. Founders
FREMONT, Calif., May 22, 2026 (GLOBE NEWSWIRE) -- The consolidation wave Litera flagged at the end of last year is here. Litera’s late-2025 outlook called it: 2026 would push the U.S. legal tech market away from scattered point solutions and toward unified platforms, with buyers actively trimming the number of vendors they work with. By mid-2026, that prediction is reflected in buyer behavior. Corporate legal departments and law firms are reducing their active vendor counts and routing more work through fewer, more integrated providers. Southeast Asian (S.E.A.) legal-tech founders entering the U.S. market now face a narrower set of buyer expectations than they did twelve months ago. Dmitry Shubov, founder of Dmitry Shubov Consulting, is weighing in on what this shift means for Southeast Asian (S.E.A.) legal-tech founders, who now face a narrower set of U.S. buyer expectations than they did twelve months ago.What U.S. acquirers and corporate buyers are prioritizing right now:
By Dmitry Shubov Consulting · Via GlobeNewswire · May 22, 2026
Transaction in Own Shares
Transaction in Own Shares
By Shell plc · Via GlobeNewswire · May 22, 2026
To music by Hélène Mercier and Daniel Lozakovich, Yacht Club de Monaco unveils its new Hemingway Cigar Lounge
MONACO, May 22, 2026 (GLOBE NEWSWIRE) -- The Yacht Club de Monaco unveiled its new Hemingway Cigar Lounge, a completely redesigned area in the heart of the Club for its members and their guests. The intimate setting combines all the elegance, discretion and culture, for which YCM is renowned, in a timeless fashion where artisanal craftsmanship takes centre stage.
By Yacht Club de Monaco · Via GlobeNewswire · May 22, 2026
BioNTech to Showcase Progress Across Late-Stage Oncology Pipeline at the 2026 ASCO Annual Meeting
MAINZ, Germany, May 22, 2026 – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will present new clinical data and trial updates from its late-stage oncology pipeline and innovative combination programs at the 2026 American Society of Clinical Oncology (“ASCO”) Annual Meeting held in Chicago, from May 29 to June 02. Two oral presentations will highlight new data for key strategic assets pumitamig and gotistobart. In addition, four trial in progress poster presentations will illustrate advancement of the Company’s ongoing pivotal trials and novel-novel combination trials, including antibody-drug conjugates (“ADC”).
By BioNTech SE · Via GlobeNewswire · May 22, 2026
Italpreziosi Achieves LMBA Silver Good Delivery Accreditation
AREZZO, Italy, May 22, 2026 (GLOBE NEWSWIRE) -- Italpreziosi S.p.A. is pleased to announce its official inclusion in the LBMA Silver Good Delivery List, one of the most prestigious international standards in the precious metals industry.
By Italpreziosi · Via GlobeNewswire · May 22, 2026
BIGC Revamps SBS LFE’s Iconic Music Show ‘THE SHOW’ as a Tech-Driven “Global Music Show”
By BIGC · Via GlobeNewswire · May 22, 2026
Together for Steatotic Liver Disease - The Hidden NCDs: SLD as the Next Global Public Health Priority
Geneva, Switzerland, May 22, 2026 (GLOBE NEWSWIRE) -- Yesterday, Global Liver Institute (GLI), in collaboration with the Egyptian Ministry of Health and Population, convened a high-level policy event, on the sidelines of the Seventy-Ninth World Health Assembly (WHA79) to translate this global policy milestone into coordinated action.
By Global Liver Institute · Via GlobeNewswire · May 22, 2026
ARKAY Launches New 200 ml Mocktail Tetra Pack Collection: A Convenient, Alcohol-Free Grab-and-Go Beverage for Modern Consumers
MIAMI, May 22, 2026 (GLOBE NEWSWIRE) -- ARKAY is proud to announce the launch of its new 200 ml Mocktail Tetra Pack Collection, a convenient, ready-to-drink line created for today’s fast-moving consumers who are looking for great taste, portability, and alcohol-free options.
By Arkay Beverages Inc · Via GlobeNewswire · May 22, 2026
Slovenian Tourist Board: Slovenia to Host the 2026 UEC Road European Championships This October
The largest cycling event in Slovenian history will bring 800 riders from 50+ countries to the roads of Slovenia — including Slovenian cycling stars Tadej Pogačar and Primož Roglič
By Slovenian Tourist Board · Via GlobeNewswire · May 22, 2026
Aegon appoints Jennifer Palmieri as Chief Human Resources Officer
Schiphol, May 22, 2026 - Aegon today announces that Jennifer Palmieri will join Aegon as Chief Human Resources Officer and member of Aegon’s Executive Committee, effective June 29, 2026. She will succeed Holly Waters who will retire as of June 1, 2026. 
By Aegon Ltd. · Via GlobeNewswire · May 22, 2026
OSE Immunotherapeutics Reports Positive Topline Results of TEDOVA Phase 2 Trial with Tedopi® in Recurrent Ovarian Cancer
OSE Immunotherapeutics Reports Positive Topline Results of TEDOVA Phase 2 Trial with Tedopi® in Recurrent Ovarian Cancer
By OSE Immunotherapeutics · Via GlobeNewswire · May 22, 2026
FRO – First Quarter 2026 Results
FRONTLINE PLC REPORTS RESULTS FOR THE FIRST QUARTER ENDED MARCH 31, 2026
By Frontline plc. · Via GlobeNewswire · May 22, 2026
VALLOUREC AND SYNGULAR SOLUTIONS SIGN A MEMORANDUM OF UNDERSTANDING TO ACCELERATE THE DEVELOPMENT OF BIOENERGY WITH CARBON CAPTURE AND STORAGE PROJECTS
 VALLOUREC AND SYNGULAR SOLUTIONS SIGN A MEMORANDUM OF UNDERSTANDING TO ACCELERATE THE DEVELOPMENT OF BIOENERGY WITH CARBON CAPTURE AND STORAGE PROJECTS
By VALLOUREC · Via GlobeNewswire · May 22, 2026
NervGen Announces Pricing of US$60.0 Million Public Offering of Securities
VANCOUVER, British Columbia, May 21, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company") (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury and other neurotraumatic and neurologic conditions, today announced the pricing of an underwritten public offering of 24,000,000 common shares and accompanying warrants to purchase up to 24,000,000 common shares. The common shares are being sold at a public offering price of US$2.50 per common share and accompanying warrant. Each accompanying warrant has an exercise price of US$3.68 per common share, and will be immediately exercisable from the date of issuance, and will expire five years from the date of issuance.
By NervGen Pharma Corp. · Via GlobeNewswire · May 21, 2026
Yimutian Inc. Announces Submission of Hearing Request to Nasdaq and Proactive Measures to Regain Full Compliance
BEIJING, May 21, 2026 (GLOBE NEWSWIRE) -- Yimutian Inc. (Nasdaq: YMT) (“Yimutian” or the “Company”), a leading agricultural digital service company in China, today announced that it has formally submitted a hearing request to the Hering Panel (the “Panel”) of The Nasdaq Stock Market LLC (“Nasdaq”) on May 20, 2026, Eastern Time.
By Yimutian Inc. · Via GlobeNewswire · May 21, 2026
Medline Inc. announces pricing of upsized secondary offering of Class A common stock
NORTHFIELD, Ill., May 21, 2026 (GLOBE NEWSWIRE) -- Medline Inc. (Nasdaq: MDLN) (“Medline”) announced today the pricing of its upsized secondary offering of 72,554,594 shares of Medline Inc.’s Class A common stock by certain selling stockholders affiliated with Blackstone Inc., Hellman & Friedman LLC and a wholly owned subsidiary of the Abu Dhabi Investment Authority (the “Selling Stockholders”) at a price to the public of $37.00 per share. The Selling Stockholders have also granted the underwriters a 30-day option to purchase up to an additional 10,883,189 shares of Medline’s Class A common stock. The offering is expected to close on May 28, 2026, subject to customary closing conditions.
By Medline Inc. · Via GlobeNewswire · May 21, 2026
GLOBAL’s AcceptAbility Gala Raises $430,000 for Down Syndrome Research and Medical Care as Celebrities and Congressional Leaders Rally Behind the Cause
Global Down Syndrome Foundation Honored Sen. Shelley Moore Capito and Rep. Paul Tonko at Event that Featured Award-Winning Multiplatinum Artist Rachel Platten and Inclusive Dance Team
AIFA Provides Update on Nasdaq Notice and Filing of Annual Report, Clearing Key Pathways for Strategic Transformation
NEW YORK, May 21, 2026 (GLOBE NEWSWIRE) -- All In FutureTech Alliance, Inc. (Nasdaq: AGAE) (the “Company” or “AIFA”) today provided an update regarding the previously received notice from the Listing Qualifications Department of The Nasdaq Stock Market.
Liminatus Pharma Announces Nasdaq Delisting Notification
FULLERTON, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- Liminatus Pharma, Inc. (Nasdaq: LIMN) (“Liminatus” or the “Company”) today announced that the Company received a delisting notice from The Nasdaq Stock Market LLC (“Nasdaq”).
By Liminatus Pharma Inc. · Via GlobeNewswire · May 21, 2026
Ascentage Pharma Releases Latest Clinical Data from Multiple Trials at ASCO 2026
ROCKVILLE, Md. and SUZHOU, China, May 21, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial-stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, today announced that six abstracts from its clinical studies, selected for presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, are now available on ASCO’s official website. Three of the six studies have been selected for rapid oral presentations, and three as poster presentation. These abstracts report data from ongoing studies evaluating the company’s three lead drug candidates, including BCR-ABL inhibitor olverembatinib(HQP1351); Bcl-2 inhibitor lisaftoclax (APG-2575); and MDM2-p53 inhibitor alrizomadlin (APG-115).
Rocket Lab Awarded $90M Contract to Build GEO Satellites Hosting Space Domain Awareness Payload for U.S. Space Force
Award marks Rocket Lab's first satellite production program for geostationary orbit and continues a Space Systems Command program for development and delivery on orbit of two Heimdall prototype payloads by Rocket Lab Optical Systems
By Rocket Lab Corporation · Via GlobeNewswire · May 21, 2026
PHR SHAREHOLDER ALERT: Securities Fraud Lawsuit Filed on Behalf of Phreesia, Inc. Investors - Contact Kirby McInerney LLP by July 13, 2026
NEW YORK, May 21, 2026 (GLOBE NEWSWIRE) -- Kirby McInerney LLP reminds investors who purchased Phreesia, Inc. (“Phreesia” or the “Company”) (NYSE:PHR) securities to contact Lauren Molinaro of Kirby McInerney LLP by email at investigations@kmllp.com, or fill out the contact form below, to discuss your rights or interests in the securities fraud class action lawsuit at no cost.
By Kirby McInerney LLP · Via GlobeNewswire · May 21, 2026
HUTCHMED Highlights Clinical Data to be Presented at the 2026 ASCO Annual Meeting
HONG KONG and FLORHAM PARK, N.J., May 22, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated data from several studies of compounds discovered by HUTCHMED will be presented at the American Society of Clinical Oncology (“ASCO”) Annual Meeting taking place from May 29 to June 2, 2026 in Chicago, USA.
By HUTCHMED (China) Limited · Via GlobeNewswire · May 21, 2026
Z INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Zillow Group, Inc.
NEW YORK, May 21, 2026 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP continues its investigation on behalf of Zillow Group, Inc. (“Zillow” or the “Company”) (NASDAQ:Z) investors concerning the Company’s and/or members of its senior management’s possible violation of the federal securities laws and other unlawful business practices.
By Kirby McInerney LLP · Via GlobeNewswire · May 21, 2026
YSS SHAREHOLDER ALERT: Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations
NEW YORK, May 21, 2026 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP reminds investors of its investigation on behalf of York Space Systems Inc. (“York Space Systems” or the “Company”) (NYSE:YSS) investors concerning the Company’s and/or members of its senior management’s possible violation of the federal securities laws or other unlawful business practices.
By Kirby McInerney LLP · Via GlobeNewswire · May 21, 2026
QGEN INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Qiagen N.V.
NEW YORK, May 21, 2026 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP continues its investigation on behalf of Qiagen N.V. (“Qiagen” or the “Company”) (NYSE:QGEN) investors concerning the Company’s and/or members of its senior management’s possible violation of the federal securities laws and other unlawful business practices.
By Kirby McInerney LLP · Via GlobeNewswire · May 21, 2026
CTEV SHAREHOLDER ALERT: Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations
NEW YORK, May 21, 2026 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP reminds investors of its investigation on behalf of Claritev Corporation (“Claritev” or the “Company”) (NYSE:CTEV) investors concerning the Company’s and/or members of its senior management’s possible violation of the federal securities laws or other unlawful business practices.
By Kirby McInerney LLP · Via GlobeNewswire · May 21, 2026
CALX INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Calix, Inc.
NEW YORK, May 21, 2026 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP continues its investigation on behalf of Calix, Inc. (“Calix” or the “Company”) (NYSE:CALX) investors concerning the Company’s and/or members of its senior management’s possible violation of the federal securities laws and other unlawful business practices.
By Kirby McInerney LLP · Via GlobeNewswire · May 21, 2026
OPCH INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Option Care Health, Inc.
NEW YORK, May 21, 2026 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP continues its investigation on behalf of Option Care Health, Inc. (“Option Care Health” or the “Company”) (NASDAQ:OPCH) investors concerning the Company’s and/or members of its senior management’s possible violation of the federal securities laws and other unlawful business practices.
By Kirby McInerney LLP · Via GlobeNewswire · May 21, 2026
Mason Street Wealth Management Introduces Vision-First Retirement Planning Approach to Help Clients Build Financial Confidence
Fresno, CA, May 21, 2026 (GLOBE NEWSWIRE) -- Mason Street Wealth Management, a leading financial services firm specializing in retirement planning, highlights its innovative vision-first financial strategy, designed to help individuals approaching retirement turn their ideal future into a structured, actionable plan. By prioritizing personal goals before financial products, the firm is redefining how retirement planning is approached in today’s evolving financial landscape.
Anker Innovations Announces Multi-Year Partnership with Tomorrowland
A multi-year partnership centered on “Ultimate Connection” through music, technology, and unforgettable live experiences
By Anker Innovations · Via GlobeNewswire · May 21, 2026
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Upstart Holdings, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – UPST
NEW YORK, May 21, 2026 (GLOBE NEWSWIRE) --
By The Rosen Law Firm PA · Via GlobeNewswire · May 21, 2026
Carolina Financial Services Group Tackles Retirement’s “Double Threat”: How Tax and Healthcare Risks Impact Retirees
Greenville, NC, May 21, 2026 (GLOBE NEWSWIRE) -- Carolina Financial Services Group, a Registered Investment Advisor firm with more than 30 years of experience in the Greenville and eastern North Carolina region as well as in the entire East Coast, is addressing the critical need for retirees to mitigate taxation and healthcare costs through a specialized, tech-enabled planning process.
Licensing Expo Concludes with Record-Breaking Show Floor and Participation from Cultural Icons, Cementing Status as Global Epicenter for Brand Collaboration
130 first-time exhibitors signal explosive growth across sports, gaming, and food & beverage, while industry heavyweights converged to shape the next wave of consumer products
By Global Licensing Group · Via GlobeNewswire · May 21, 2026
Anker Unveils Next-Generation Products Across Brands at Anker Day 2026
From immersive audio to smart home security, Anker Innovations' portfolio debuts breakthrough technology at annual showcase
By Anker Innovations · Via GlobeNewswire · May 21, 2026
GEHC INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving GE HealthCare Technologies Inc.
NEW YORK, May 21, 2026 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP continues its investigation on behalf of GE HealthCare Technologies Inc. (“GE HealthCare” or the “Company”) (NASDAQ:GEHC) investors concerning the Company’s and/or members of its senior management’s possible violation of the federal securities laws and other unlawful business practices.
By Kirby McInerney LLP · Via GlobeNewswire · May 21, 2026
ATEC INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Alphatec Holdings, Inc.
NEW YORK, May 21, 2026 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP continues its investigation on behalf of Alphatec Holdings, Inc. (“Alphatec” or the “Company”) (NASDAQ:ATEC) investors concerning the Company’s and/or members of its senior management’s possible violation of the federal securities laws and other unlawful business practices.
By Kirby McInerney LLP · Via GlobeNewswire · May 21, 2026
POET SHAREHOLDER ALERT: Securities Fraud Lawsuit Filed on Behalf of POET Technologies Inc. Investors - Contact Kirby McInerney LLP by June 29, 2026
NEW YORK, May 21, 2026 (GLOBE NEWSWIRE) -- Kirby McInerney LLP reminds investors who purchased POET Technologies Inc. (“POET” or the “Company”) (NASDAQ:POET) securities to contact Lauren Molinaro of Kirby McInerney LLP by email at investigations@kmllp.com, or fill out the contact form below, to discuss your rights or interests in the securities fraud class action lawsuit at no cost.
By Kirby McInerney LLP · Via GlobeNewswire · May 21, 2026
EMGA arranges USD 15m financing for Asia Alliance Bank from OeEB
LONDON, May 21, 2026 (GLOBE NEWSWIRE) -- Emerging Markets Global Advisory LLP is delighted to announce yet another closing in Uzbekistan having secured funding from OeEB, the Development Bank of Austria, to support Asia Alliance Bank.
CLARITEV STOCKHOLDER ALERT: Bragar Eagel & Squire, P.C. is Investigating Claritev Corporation on Behalf of Claritev Stockholders and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Claritev (CTEV) To Contact Him Directly To Discuss Their Options
By Bragar Eagel & Squire · Via GlobeNewswire · May 21, 2026
Biogen and Denali Therapeutics Provide Update on Phase 2b LUMA Study of BIIB122 (DNL151) in Early-Stage Parkinson’s Disease
CAMBRIDGE, Mass. and SOUTH SAN FRANCISCO, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Denali Therapeutics Inc. (Nasdaq: DNLI) today announced topline results from the Phase 2b LUMA study evaluating BIIB122 (DNL151), an investigational small molecule inhibitor of LRRK2 (leucine-rich repeat kinase 2), in individuals with early-stage Parkinson’s disease. Results from the study show that BIIB122 did not slow the progression of Parkinson’s disease versus placebo, as measured by the primary endpoint of Time to Confirmed Worsening in the modified Movement Disorder Society Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) Part II and III combined score. Secondary endpoints also did not show a benefit with BIIB122. Exploratory biomarker endpoints demonstrated >90% kinase inhibition of peripheral LRRK2 (phosphoserine 935) and, in a cerebrospinal fluid (CSF) sub-study, up to approximately 30% reduction observed in a biomarker of LRRK2 activity (phosphorylated Rab10). Expected levels of BIIB122 in the blood and CSF were sustained across the study. BIIB122 was generally well tolerated with an acceptable safety profile. Based on these results, Biogen and Denali will discontinue further development of BIIB122 in idiopathic Parkinson’s disease. Denali will continue to independently conduct the Phase 2a BEACON study evaluating the small molecule inhibitor in carriers of a pathogenic LRRK2 variant.
By Denali Therapeutics Inc. · Via GlobeNewswire · May 21, 2026
Samba TV Launches Project Gravity, an Independent Data Activation Platform for the Agentic Era
Project Gravity provides advertisers and data owners with a neutral platform that onboards and activates their first party data across Google DV360, The Trade Desk, Meta, TikTok, Amazon, Magnite, and many other Samba partners
By Samba TV · Via GlobeNewswire · May 21, 2026
nVent to Participate in Upcoming Investor Conference
LONDON, May 21, 2026 (GLOBE NEWSWIRE) -- nVent (NYSE: NVT), a global leader in electrical connection and protection solutions, today announced its participation in William Blairs 46th Annual Growth Stock Conference on Wednesday, June 3, 2026. Beth Wozniak, Chair and Chief Executive Officer, will present at 8:00 a.m. CST.
By nVent · Via GlobeNewswire · May 21, 2026
YORK SPACE SYSTEMS INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating York Space Systems Inc. on Behalf of York Space Systems Stockholders and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In York Space Systems (YSS) To Contact Him Directly To Discuss Their Options
By Bragar Eagel & Squire · Via GlobeNewswire · May 21, 2026
Crescent Biopharma Announces Trial in Progress Presentation for ASCEND Study of CR-001, a PD-1 x VEGF Bispecific Antibody, at Upcoming American Society of Clinical Oncology (ASCO) 2026 Annual Meeting
ASCEND Phase 1/2 global clinical trial evaluating CR-001 in multiple solid tumor types, including NSCLC, gastrointestinal and gynecological cancers in first-line and previously treated patients
By Crescent Biopharma, Inc. · Via GlobeNewswire · May 21, 2026
Pliant Therapeutics Announces Upcoming Presentation at the 2026 American Society of Clinical Oncology Annual Meeting
Highlights FORTIFY, the Phase 1b indication expansion trial of PLN-101095 enrolling patients with ICI-refractory solid tumors
By Pliant Therapeutics, Inc. · Via GlobeNewswire · May 21, 2026
BLACK ROCK COFFEE BAR ALERT: Bragar Eagel & Squire, P.C. is Investigating Black Rock Coffee Bar, Inc. on Behalf of Black Rock Stockholders and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Black Rock (BRCB) To Contact Him Directly To Discuss Their Options
By Bragar Eagel & Squire · Via GlobeNewswire · May 21, 2026
Aktis Oncology Reports First-in-Human Clinical Imaging and Dosimetry Data for AKY-2519 Demonstrating Robust Tumor Uptake and Limited Normal Tissue Exposures in Patients with B7-H3 Expressing Tumors
BOSTON, May 21, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. (NASDAQ:AKTS) (Aktis or the Company), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large populations, including those not addressed by existing platform technologies, today reported first-in-human clinical imaging and dosimetry data for AKY-2519, a miniprotein radioconjugate targeting B7-H3 expressing tumors. The data from two separate assessments of AKY-2519 – a clinical imaging and dosimetry assessment in patients with mCRPC and a clinical imaging assessment in patients with various solid tumor types – demonstrated robust tumor uptake and limited normal tissue exposure. These findings, which supported the advancement of a broad clinical development program for AKY-2519, will be presented in two poster presentations at the upcoming 2026 ASCO Annual Meeting, being held May 29 – June 2, 2026, in Chicago.
By Aktis Oncology Inc. · Via GlobeNewswire · May 21, 2026
COMMVAULT INVESTOR ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Commvault Systems, Inc. and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Commvault (CVLT) To Contact Him Directly To Discuss Their Options
By Bragar Eagel & Squire · Via GlobeNewswire · May 21, 2026
SPORTRADAR LAWSUIT ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Sportradar Group AG and Encourages Investors to Contact the Firm
NEW YORK, May 21, 2026 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Sportradar (SRAD) To Contact Him Directly To Discuss Their Options
By Bragar Eagel & Squire · Via GlobeNewswire · May 21, 2026
Black Diamond Therapeutics Announces Positive Phase 2 Results for Silevertinib in Frontline NSCLC Patients with EGFR Non-Classical Mutations
CAMBRIDGE, Mass., May 21, 2026 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, today announced positive results from its Phase 2 trial of silevertinib in frontline (1L) non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) non-classical mutations (NCMs). These data will be presented by Julia Rotow, M.D., Clinical Director, Lowe Center for Thoracic Oncology at the Dana-Farber Cancer Institute, at the 2026 American Society of Clinical Oncology® (ASCO®) Annual Meeting on Saturday, May 30, 2026, 1:15 PM-2:45 PM CDT.
Autolus Therapeutics to Present Clinical Data Update at the American Society of Clinical Oncology Annual Meeting 2026
LONDON and GAITHERSBURG, Md., May 21, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies and candidates, announces the online publication of an abstract submitted to the American Society of Clinical Oncology (ASCO) Annual Meeting, to be held May 29 – June 2, 2026, in Chicago, Illinois.
By Autolus Therapeutics plc · Via GlobeNewswire · May 21, 2026
Equus Announces First Quarter Net Asset Value
HOUSTON, May 21, 2026 (GLOBE NEWSWIRE) -- Equus Total Return, Inc. (NYSE: EQS) (“Equus” or the “Company”) reports net assets as of March 31, 2026, of $20.9 million. Net asset value per share increased to $1.50 as of March 31, 2026, from $1.19 as of December 31, 2025. Comparative data is summarized below (in thousands, except per share amounts):  
By Equus Total Return, Inc · Via GlobeNewswire · May 21, 2026
ROSEN, THE FIRST FILING FIRM, Encourages SES AI Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – SES
NEW YORK, May 21, 2026 (GLOBE NEWSWIRE) --
By The Rosen Law Firm PA · Via GlobeNewswire · May 21, 2026
Whale Dynamic Joins Hitch Open World AI Championships as Official Mapping Technology Partner, Delivering Centimeter-Accurate HD Map of Tianmen Mountain for 2026 Racing Season
SAN FRANCISCO and SHENZHEN, China and ZHANGJIAJIE, China, May 21, 2026 (GLOBE NEWSWIRE) -- Hitch Open World AI Championships and Whale Dynamic today announced that their strategic partnership has entered full-scale delivery. Whale Dynamic will provide all Hitch Open competing teams with a centimeter-accurate 3D high-definition (HD) map covering the entire 10.77-kilometer Tianmen Mountain course—featuring 1,100 meters of elevation change and 99 consecutive hairpin turns—as the unified localization baseline for the Hitch Open World AI Racing Championships 2026, scheduled for June 25–26 in Zhangjiajie, China.
By Hitch Interactive · Via GlobeNewswire · May 21, 2026
North American Construction Group Ltd. Announces Voting Results of Annual and Special Meeting of Shareholders
ACHESON, Alberta, May 21, 2026 (GLOBE NEWSWIRE) -- North American Construction Group Ltd. (“NACG” or “the Company”) (TSX:NOA/NYSE:NOA) today announced the results of its Annual and Special Meeting of Shareholders held on May 20, 2026.  Shareholders elected directors, approved the appointment of KPMG LLP as the independent auditors of the Company, approved a non-binding advisory vote regarding the Company’s approach to executive compensation and ratified an Advance Notice Bylaw.  The following are the results of the votes held at the meeting:
Eikon Therapeutics Announces Availability of Six Abstracts for Presentation at the 2026 Annual Meeting of the American Society of Clinical Oncology
MILLBRAE, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (“Eikon”), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, today announced the publication of full-text abstracts from its lead programs to be presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago beginning on 29 May 2026. The six accepted presentations highlight clinical progress across Eikon’s pipeline, including the TLR7 and TLR8 dual-agonist EIK1001 trials in NSCLC and advanced melanoma, updated data for its highly selective PARP1 inhibitor EIK1003, and early development progress for the WRN inhibitor candidate EIK1005.
By Eikon Therapeutics, Inc. · Via GlobeNewswire · May 21, 2026
Remix Therapeutics Announces Positive Data from Phase 1/2 ARIA Study of First-in-Class MYB mRNA Degrader, REM-422, in Patients with Adenoid Cystic Carcinoma (ACC) at the American Society of Clinical Oncology Annual Meeting 2026
Phase 1 Data Shows a 43% Overall Response Rate at the Recommended Phase 2 Dose and Durable Responses Exceeding One Year and Ongoing, with a Favorable Safety Profile
By Remix Therapeutics · Via GlobeNewswire · May 21, 2026